Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review

BACKGROUND: Recently, two phase II trials showed intracranial activity of the immune checkpoint inhibitors nivolumab and ipilimumab in patients with melanoma brain metastases. However, it is generally assumed that large molecules like monoclonal antibodies nivolumab and ipilimumab cannot penetrate a...

Descripción completa

Detalles Bibliográficos
Autores principales: van Bussel, Mark T. J., Beijnen, Jos H., Brandsma, Dieta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543612/
https://www.ncbi.nlm.nih.gov/pubmed/31146733
http://dx.doi.org/10.1186/s12885-019-5741-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543612/
https://www.ncbi.nlm.nih.gov/pubmed/31146733
http://dx.doi.org/10.1186/s12885-019-5741-y

Ejemplares similares